This study was performed to investigate the platelet aggregation alterations in platelet-rich plasma (PRP) samples of children with Helicobacter pylori (H pylori) infection. Platelet aggregation induced by adenosine diphosphate (ADP), collagen, ristocetin, or epinephrine was studied with photometric aggregometry in 30 patients before and after eradication therapy and in a control group including 15 children. The pretreatment mean maximum aggregation values and slope were significantly lower (P < .0001) in the study group at 10 mmol/L concentrations of ADP (ADP-like defect). The maximum aggregation values and slope revealed no significant differences (P > 0.05) between the study group after therapy and the control group. We concluded that H pylori infection may cause dysfunction of platelets in children and can be reversed by H pylori eradication therapy. Further studies should be carried out to determine the mechanisms of platelet dysfunction in children with H pylori infection.
Introduction
Helicobacter pylori (H pylori) is a small, highly motile, gramnegative bacillus. 1 Helicobacter pylori is the most common gastrointestinal chronic bacterial infection in the world, colonizing the stomachs of more than 50% of the human population. 2 Helicobacter pylori is an important pathogen, which causes chronic gastritis and peptic ulcers, and has been associated with gastric adenocarcinoma and lymphoma. 3, 4 In addition, many reports purport to show that the organism causes a variety of intestinal and extraintestinal manifestations in children. Helicobacter pylori possibly causes gastroesophageal reflux disease, iron deficiency anemia, pernicious anemia, autoimmune thrombocytopenia, and growth retardation. [5] [6] [7] Recent studies have suggested that chronic infections with H pylori may be associated with the risk of coronary heart disease and stroke. [8] [9] [10] [11] [12] Helicobacter pylori infection induces a marked increase in the flux of rolling leukocytes and the appearance of platelet and leukocyte-platelet aggregates in murine gastric venules. 13, 14 Chronic infection of mice with H pylori leads to increased platelet embolization after damage to the arterioles. 15 Various animal model studies showed that H pylori infection induced local platelet aggregate formation in gastric and mesentery circulation. In addition, some strains of H pylori induce platelet activation mediated by H pylori-bound von Willebrand factor (vWF) interacting with glycoprotein Ib (GPIb) and supported by immunoglobulin G (IgG). These platelet-H pylori interactions may contribute to the pathogenesis of H pylori-associated peptic ulcer disease and to the association between H pylori infection and cardiovascular disease, whereas local platelet effects may contribute to the pathogenesis of H pylori-associated peptic ulcer disease. 16 All these studies have raised a question as to whether H pylori infection affects platelet functions. However, there is, to our knowledge, no study published aiming to demonstrate this possible interaction in humans. This study was performed to investigate the platelet aggregation alterations in platelet-rich plasma (PRP) samples of children with H pylori infection and to demonstrate the probable effects of H pylori eradication treatment on platelet aggregation.
Materials and Methods
This study was performed at the Department of Pediatrics of Gulhane Military Medical Academy. A total of 30 children, who suffered from abdominal pain, nausea, vomiting or lack of appetite and diagnosed to have H. pylori infection constituted the study group (group 1). Of these, 15 were male and 15 were female, and their ages ranged between 6 to 15 years. The control group (group 2) consisted of 15 children, who complained about abdominal pain, nausea or lack of appetite and diagnosed to have functional abdominal pain without H. pylori infection. Among these 15 cases, 8 were male and 7 were female, and their ages ranged from 6 to 15 years. There were no statistically significant differences between the study and control groups with respect to age and gender (P > .05). Written informed consent was obtained from the parents of the cases in both groups, and the study was approved by the local ethics committee.
The presence of the following criteria was necessary for entry into the study in both the study and the control groups: (1) no ingestion of any known antiplatelet agent, such as salicylates, antibiotics, H2 receptor blockers, proton pump inhibitors, or bismuth-containing drugs in the last 30 days; (2) no other systemic illnesses, such as cardiac, renal, and hepatic diseases, other than H pylori infection; (3) C-14 urea breath test compatible with H pylori infection for the cases in the study group; and (4) functional abdominal pain without H pylori infection for the cases in the control group.
In both the study and the control groups, complete blood count (CBC), ferritin, prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen, C-reactive protein (CRP), and vWF measurements were performed. Children in the study group were given a 2-week course of oral lansoprazole with a daily dose of 1 mg/kg in a single dose, amoxicilline with a daily dose of 40 mg/kg in three doses, and clarithromycine with a daily dose of 20 mg/kg in two doses (Proton pump inhibitor plus Amoxicilline plus Clarithromycine [PAC] therapy). 17 Six patients who failed to respond to PAC therapy received the second-line PAC regimen, resulting in an eradication rate of 100%. In these patients, platelet aggregation was studied before and after H pylori eradication therapy, whereas it was studied once in the control group at the study entry. Considering that the antibiotic use may affect platelet aggregation function, the second aggregation studies were performed 15 days after the completion of the PAC therapy.
Erythrocyte indices, platelet counts, and mean platelet values were determined by the automated equipment (Technicon H-1 System; Technicon Co, Tournai, Belgium).
C14-Urea breath test was performed by the previously described method. 18 The Advia Centaur ferritin assay is a 2site sandwich immunoassay that uses direct chemiluminometric technology with constant amounts of 2 ferritin antibodies. The values less than 10 ng/mL were described hypoferritinemia. C-reactive protein was assessed using an immunoturbidimetric assay (C-reactive Protein Scil One, No: KRS0202; Scil Diagnostics GmBH, Martinsried, Germany). The values more than 6 mg/L were accepted as positive. von Willebrand Factor was assessed using an immunoturbidimetric assay (STA-Liatest vWF, No: 518, Diagnostica Stago, France). The values more than 160% were accepted as positive.
The blood samples were drawn from the antecubital vein without venous occlusion into plastic syringes containing 1/ 10 volume of 3.8% trisodium citrate. Platelet-rich plasma and platelet-poor plasma were prepared by centrifuging as described previously. 19 Platelet aggregation was measured by the photometric aggregometry method using the Whole Blood Aggregometer Model 560 (Chrono-Log Corporation, Havertown, PA).
Collagen (5 mg/mL, Chrono Par No: 385, Chrono-Log Corporation), adenosine diphosphate (ADP; 10 mmol/L, Chrono Par No: 384; Chrono-Log Corporation), epinephrine (10 mmol/L, Chrono-Par No: 393; Chrono-Log Corporation), and ristocetin (1.5 mg/mL, Biopool No: 50705; Trinity Biotech, Bray, Co, Wicklow, Ireland) were used as agonists. The slope and maximum aggregation value were determined from the aggregation curves and defined as %/min and %, respectively. The effects of ADP, collagen, ristocetin, and epinephrine on aggregation in the control and study groups were evaluated regarding the reducing effect of iron deficiency and the excitatory effect of high-level vWF on aggregation. 20, 21 Results are expressed as means + standard error of the mean (SEM), depending on the distribution of data (n ¼ the number of patients). Statistical comparisons between the 2 groups were made using Student t test for independent or dependent samples when sample distribution was normal or using nonparametric Mann-Whitney U test for samples without normal distribution. Correlations were assessed using Pearson statistics. P values of <.05 were considered statistically significant.
Results
In the study group, 5 patients had pretreatment hypoferritinemia and 3 patients had pretreatment vWF levels above the 160% value. The study group posttreatment ferritin and vWF levels and control group ferritin and vWF levels were normal. Study group pre and posttreatment CRP values and control group CRP values were normal.
The study group pretreatment and posttreatment parameters and control group parameters did not differ significantly in values for plasma ferritin, PT, INR, activated PTT (aPTT), CRP, fibrinogen, and vWF (P > .05; Table 1 ).
Platelet Aggregation Studies With ADP
The mean maximum aggregation value and slope induced by 10 mmol/L ADP in the study group before (n ¼ 30) and after treatment (n¼30) and in the control group (n ¼ 15) are shown in Tables 2, 3, and 4.
In the study group, at 10 mmol/L concentration of ADP, the posttreatment mean maximum aggregation value and slope were significantly higher than the pretreatment values (P < .0001 and P ¼ .001, respectively). In the study group, the pretreatment maximum aggregation and slope values were significantly lower than those in the control group (P < .0001 and P ¼ .023, respectively). No statistically significant differences were found between the study group posttreatment values and the control group with respect to mean maximum aggregation value and slope (P > .05).
Platelet aggregation studies with ADP between the study group without iron deficiency and control group. In the study group without iron deficiency (n ¼ 25), the posttreatment mean maximum aggregation value and slope were significantly higher than the pretreatment values (P < .0001 and P ¼ .001, respectively). In the study group, the pretreatment maximum aggregation and slope values were significantly lower than those in the control group (P < .0001 and P ¼ .008, respectively). No statistically significant differences were found between the study group posttreatment values and the control group with respect to mean maximum aggregation value and slope (P > .05).
Platelet aggregation studies with ADP between the study group with normal levels of vWF and control croup. In the study group with normal vWF levels (n ¼ 27), the posttreatment mean maximum aggregation value and slope were significantly higher than the pretreatment values (P < .0001 and P ¼ .006, respectively). In the study group, the pretreatment maximum aggregation and slope values were significantly lower than those in the control group (P < .0001 and P ¼ .02, respectively). No statistically important differences were found between the study group posttreatment values and the control group with respect to mean maximum aggregation value and slope (P > .05).
Platelet Aggregation Studies With Collagen, Ristocetin, and Epinephrine
There were no statistically significant differences among the pretreatment, posttreatment, and control groups with respect to mean maximum aggregation value and slope at final concentrations of 5 mg/mL for collagen, 1.5 mg/mL for ristocetin, and 10 mmol/L for epinephrine (P > .05; Table 5 ).
Discussion
This is the first report that evaluates the platelet aggregation alterations in PRP samples of children with H pylori infection. The ADP, collagen, ristocetin, and epinephrine aggregation responses of platelets were evaluated on the PRP samples of the children infected with H pylori and these results were compared with the controls.
In this study, we demonstrated that H pylori infection in children may significantly decrease platelet response to ADP (ADP-like defect), which can be reversed by eradication therapy. 22 Although we did not measure the nitric oxide (NO) levels in the serum, the platelet aggregation dysfunction of children with H pylori infection may be related to elevated NO levels. Inducible NO-synthase (iNOS) is expressed after activation by proinflammatory cytokines in macrophages, endothelial cells, platelets, and other cells, and NO strongly inhibits platelet aggregation. 23 Nitric oxide acts as a messenger in various inflammatory pathways and contributes to defense mechanisms against microorganisms. It has been reported that H pylori infection induces NO synthesis. iNOS levels are upregulated in a subgroup of patients with chronic active gastritis. 24 Recombinant H pylori urease was shown to directly stimulate macrophage iNOS expression. 25 Both plasma endothelin-1 (ET-1) and nitrate/nitrite levels have been shown to be increased in patients with active duodenal ulcer. 26 The patients had diminished blood ET-1 level and elevated nitrate/nitrite level after an effective H pylori eradication therapy.
The other potential mechanism of platelet dysfunction with H pylori infection may be related to H pylori lipopolysaccharide (LPS). Studies on platelet function on sepsis have yielded conflicting results. In a lethal endotoxin shock model in dogs, Almqvist et al reported increased platelet aggregation and others have also shown endotoxin-induced platelet accumulation and enhanced platelet aggregation in animal models. [27] [28] [29] Staphylococcus aureus lipoteichoic acid (LTA) inhibited platelet aggregation in human platelets stimulated by agonists. Lipoteichoic acid also inhibited intracellular calcium (Ca þþ ) mobilization in human platelets stimulated by collagen. In addition, LTA increased the formation of cyclic AMP but not cyclic GMP in platelets. These results indicate that the antiplatelet activity of LTA may be involved in the increase of cyclic AMP, leading to the inhibition of intracellular Ca þþ mobilization and protein kinase C activity. Therefore, LTA-mediated alteration of platelet function may contribute to bleeding diathesis in septicemic and endotoxemic patients. 30 Escherichia coli LPS inhibited platelet aggregation in human and rabbit platelets stimulated by agonists. Lipopolysaccharide also dose dependently inhibited the intracellular Ca þþ mobilization in human platelets stimulated by collagen. In addition, LPS significantly increased the production of nitrate, the formation of cyclic GMP, but not cyclic AMP in platelets. 31, 32 In this respect, H pylori LPS may be expected to inhibit platelet function. There is no study published aiming to demonstrate H pylori LPS and platelet interaction in humans. However, it has been reported that H pylori DNA exists in atherosclerotic plaques of adults and H pylori DNA positiveness is 37% to 52% in endarterectomy materials. 33, 34 This is an important point as it remarks not only local but also the systemic effects of H pylori.
Animal model studies using fluorescent in vivo microscopy have shown that H pylori infection alters blood flow, the endothelial lining of the vessels, and leukocyte activity and often induces the formation of circulating or adherent platelet aggregates, consistent with epidemiological studies that suggest a possible association between H pylori infection and the incidence of cardiovascular diseases. 13, 15, 16, 35, 36 These platelet-H pylori interactions may contribute to the pathogenesis of H pylori-associated peptic ulcer disease and to the association between H pylori infection and cardiovascular disease, whereas local platelet effects may contribute to the pathogenesis of H pylori-associated peptic ulcer disease. These studies were performed in animals, and there is, to our knowledge, no study published aiming to demonstrate this possible interaction in humans. We conclude that H pylori infection in children may cause dysfunction of the PRP platelet aggregation and can be reversed by H pylori eradication therapy. Further studies should be carried out to determine whether the platelet aggregation dysfunction in H pylori infection is due to an elevation of NO levels.
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